Abstract
We tested the antiviral susceptibilities of 30 clinical isolates of herpes simplex virus using the microplate in situ enzyme-linked immunosorbent assay (MISE) and the plaque reduction assay (PRA). There was concordance for 26 of 30 acyclovir results and all 30 foscarnet results. MISE and PRA results each predicted the response to acyclovir in 12 of 14 instances and the response to foscarnet in 8 instances. MISE is more rapid than PRA, has an objective endpoint, and correlates well with the clinical response to therapy.
Full Text
The Full Text of this article is available as a PDF (154.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Leahy B. J., Christiansen K. J., Shellam G. Standardisation of a microplate in situ ELISA (MISE-test) for the susceptibility testing of herpes simplex virus to acyclovir. J Virol Methods. 1994 Jun;48(1):93–108. doi: 10.1016/0166-0934(94)90092-2. [DOI] [PubMed] [Google Scholar]
- Martin J. L., Ellis M. N., Keller P. M., Biron K. K., Lehrman S. N., Barry D. W., Furman P. A. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates. Antimicrob Agents Chemother. 1985 Aug;28(2):181–187. doi: 10.1128/aac.28.2.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McLaren C., Ellis M. N., Hunter G. A. A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents. Antiviral Res. 1983 Nov;3(4):223–234. doi: 10.1016/0166-3542(83)90001-3. [DOI] [PubMed] [Google Scholar]
- Parris D. S., Harrington J. E. Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother. 1982 Jul;22(1):71–77. doi: 10.1128/aac.22.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Safrin S., Elbeik T., Phan L., Robinson D., Rush J., Elbaggari A., Mills J. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1994 Jun;38(6):1246–1250. doi: 10.1128/aac.38.6.1246. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Safrin S., Kemmerly S., Plotkin B., Smith T., Weissbach N., De Veranez D., Phan L. D., Cohn D. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis. 1994 Jan;169(1):193–196. doi: 10.1093/infdis/169.1.193. [DOI] [PubMed] [Google Scholar]
- Safrin S., Phan L., Elbeik T. A comparative evaluation of three methods of antiviral susceptibility testing of clinical herpes simplex virus isolates. Clin Diagn Virol. 1995 Jul;4(1):81–91. doi: 10.1016/0928-0197(94)00059-4. [DOI] [PubMed] [Google Scholar]
- Swierkosz E. M., Scholl D. R., Brown J. L., Jollick J. D., Gleaves C. A. Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus. Antimicrob Agents Chemother. 1987 Oct;31(10):1465–1469. doi: 10.1128/aac.31.10.1465. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tebas P., Stabell E. C., Olivo P. D. Antiviral susceptibility testing with a cell line which expresses beta-galactosidase after infection with herpes simplex virus. Antimicrob Agents Chemother. 1995 Jun;39(6):1287–1291. doi: 10.1128/aac.39.6.1287. [DOI] [PMC free article] [PubMed] [Google Scholar]